Vitreous detachment
disease diseaseOn this page
Also known as detachment Of vitreousvitreous, detachment Of
Summary
Vitreous detachment (MONDO:0007017) is a disease and 6 clinical trials. Top therapeutic interventions include sevoflurane and hyaluronidase (ovine). A subtype of vitreous disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 6
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | vitreous detachment |
| Mondo ID | MONDO:0007017 |
| EFO | EFO:1001238 |
| MeSH | D020255 |
| DOID | DOID:9726 |
| NCIT | C50807 |
| SNOMED CT | 53772007 |
| UMLS | C0423361 |
| MedGen | 140839 |
| GARD | 0024519 |
| MedDRA | 10047650 |
| Is cancer (heuristic) | no |
Also known as: detachment Of vitreous · vitreous, detachment Of
Disease family
This is a subtype of vitreous disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye disorder › vitreous body disorder › vitreous disorder › vitreous detachment
Related subtypes (3): vitreous syneresis, vitreous abscess, persistent hyperplastic primary vitreous
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 6.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 4 |
| PHASE4 | 1 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04346095 | PHASE4 | UNKNOWN | Oral Sedation in Vitreoretinal Surgery |
| NCT00198471 | PHASE2 | COMPLETED | Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment |
| NCT02783209 | Not specified | TERMINATED | Effect on the Vitreous of the Not Complicated Surgery of the Cataract to the Emmetropic Patient |
| NCT03970148 | Not specified | UNKNOWN | YAG Laser Vitreolysis for Floaters |
| NCT04865991 | Not specified | COMPLETED | Comparison of Propofol Target Controlled Infusion (TCI) and Sevoflurane |
| NCT05249413 | Not specified | COMPLETED | Early Vitrectomy for Endophthalmitis After Cataract Surgery |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| SEVOFLURANE | 4 | 1 |
| HYALURONIDASE (OVINE) | 3 | 1 |
Related Atlas pages
- Drugs: Sevoflurane, Hyaluronidase (Ovine)